The goal of the NHLBI Progenitor Cell Biology Consortium (PCBC) is to identify and characterize progenitor cell lineages, to direct the differentiation of stem and progenitor cells to desired cell fates, and to develop new strategies to address the unique challenges presented by the transplantation of these cells.
The National Heart, Lung, and Blood Institute in 2025: What If…
NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25)
FOA #: RFA-MD-15-005
The 7th Annual PCBC Meeting will be held at Houston Methodist Research Institute, from October 13-14, 2015. A Fellows-Only Session will be held on October 12, 2015.
More details to come.
Dr. Joseph Wu and colleagues cordially invite you to attend the upcoming Cardiovascular Tissue Engineering Symposium at Stanford. This event, sponsored by the Stanford Cardiovascular Institute, features a number of PCBC investigators and is free of charge to all PCBC members.
Tenascin C Promotes Hematoendothelial Development and T Lymphoid Commitment from hPSCs in Chemically Defined Conditions
Gene Uenishi, a graduate student, in Dr. Igor Slukvin’s laboratory under the Thomson Hub Site 02 at the University of Wisconsin – Madison, has recently published an article titled, “Tenascin C Promotes Hematoendothelial Development and T Lymphoid Commitment from Human Pluripotent Stem Cells in Chemically Defined Conditions” in the Stem Cell Reports.
Platform for Sharing and Accessing Available Protocols and Reagents
The PCBC Synapse platform, in addition to storing data is a resource for the aggregation and dissemination of protocols and reagents for the consortium.
The Director of the NHLBI, Dr. Gary Gibbons, has provided a report about the progress made during Fiscal Year 2014 and the forecast for funding opportunities in FY15.
Please see the attachment to read Dr. Gibbons message to the NHLBI scientific community.